Tag: patient safety

NEW YORK (Reuters Health) – A meta-analysis confirms that ovarian cyst development is a common side effect of treatment with a mammalian target of rapamycin inhibitor (mTORi). In their paper in BMJ Open, the researchers note that the mTOR-signaling pathway regulates ovarian function, so it’s conceivable that mTORi may affect ovarian activity. Observational data suggest

In a new practice advisory, an international team of experts discussed the use of gadolinium-based contrast agents (GBCAs), an alternative to iodinated contrast media, in interventional pain procedures. The evidence-based position statement weighed the risks of using GBCAs and provided recommendations to standardize practices and maintain patient safety. Physicians typically use iodinated contrast agents (ICAs)

Peloton is pushing back against a U.S. government warning about the safety of its pricey home-use treadmill. Experts wonder if it’s a case of dangerous design flaws — or the need for individual users to be accountable. It’s being followed closely as the at-home, artificial-intelligence-assisted fitness machines get more popular — and as gyms reopen

FRANKFURT (Reuters) – German biotech firm CureVac said it has seen the number of requests for its experimental COVID-19 vaccine increase over the past few days, as concerns over rare side effects have hit some other coronavirus shots. A CureVac spokesman said on Thursday that requests have been coming in from various quarters, including governments

Tamoxifen has long been used in breast cancer, both in the adjuvant and preventive setting, but uptake and adherence are notoriously low, mainly because of adverse events. Using a much lower dose to reduce the incidence of side effects would be a “way forward,” reasoned Swedish researchers. They report that a substantially lower dose of

(Reuters Health) – Daily relugolix therapy cuts menstrual bleeding by at least half without affecting bone density in 71% of women with uterine fibroids, according to results from the LIBERTY 2 trial, published by The New England Journal of Medicine. The oral gonadotropin-releasing hormone (GnRH) receptor antagonist from Myovant Sciences, approved by the U.S. Food